The Economist Health Focus 2026

Democratization of Weight Loss:

Ozempic, but better

Oral pills, patent cliffs, and the arrival of ‘Godzilla’ drugs

Injections are over. The era of the pill is here.
For the past decade, the weight-loss drug market has been dominated by ‘injectables (GLP-1)’. Global spending reached $54 billion in 2024 alone. But in 2026, the rules of the game will change. More potent, cheaper, and more convenient ‘second-generation weight-loss drugs’ are flooding the market. Here are the three keywords defining the revolution in the 2026 obesity market, as forecasted by The Economist.

💊 1. The Rise of Oral Pills

Drugs like Wegovy and Zepbound required weekly injections and refrigeration, complicating distribution. In 2026, proven oral treatments will finally enter the market.

Novo Nordisk

Oral Semaglutide

Expected Efficacy: 16.6% weight loss after one year.
Key Feature: Delivers the same active ingredient as existing injectables (Wegovy) in pill form.

Eli Lilly

Orforglipron

Expected Efficacy: 12.4% weight loss after one year.
Key Feature: While slightly less effective than injections, it is stable at room temperature, promising widespread adoption in developing nations lacking cold-chain infrastructure.

🦖 2. The ‘Godzilla’ of New Drugs

While pills offer convenience, next-generation injectables compete on overwhelming efficacy. ‘Multi-receptor agonists’ that target several metabolic pathways simultaneously are awaiting Phase 3 trial results.

Drug (Maker)
Type
Clinical Results & Features

Retatrutide
(Eli Lilly)
Triple Agonist
Dubbed the ‘Godzilla of weight-loss drugs’.
Phase 2 showed 24% weight loss in 48 weeks.
(Comparable to bariatric surgery)

CagriSema
(Novo Nordisk)
Combination
Combines Wegovy + Amylin analogue.
Demonstrated 23% weight loss in Phase 3.

MariTide
(Amgen)
Long-acting
Injected ‘once monthly’ instead of weekly.
Expected 20% loss after one year with reduced rebound effects.

💪 Lose Fat, Keep Muscle?
To address the ‘muscle loss’ drawback of existing drugs, Lilly is developing an antibody drug called Bimagrumab. When combined with semaglutide, results showed that 93% of weight lost was pure fat (compared to 72% with semaglutide alone).

🌏 3. Patent Cliffs & Mass Adoption

2026 marks the beginning of the ‘Patent Cliff’ for weight-loss drugs. Patents for semaglutide (the ingredient in Ozempic/Wegovy) will expire in major emerging markets like Brazil, China, and India. This signals the era of affordable generics.

80%

Expected Price Drop (India)

30+

New Drugs in Dev (China)

India already has over 10 generic versions in clinical trials, expected to slash prices to one-fifth of current levels upon release. China is also set to become a base for supplying ‘low-cost weight-loss drugs’ globally through licensing deals or domestic generics.

🍔 The Butterfly Effect on Industry & Society

The democratization of weight-loss drugs is not just a pharmaceutical issue.

📉 Crisis in Big Food: Appetite suppression could lead to a structural decline in the consumption of snacks, soda, and fast food.
❤️ Health Rediscovered: It’s not just about weight. Studies are showing benefits for cardiovascular disease, sleep apnea, kidney disease, and even addiction.
🤔 Ethical Debate: As weight loss becomes accessible to all, society will face a debate: Is relying on medication ‘cheating’, or is it an essential ‘assistive tool’ like eyeglasses?

📝 Conclusion for 2026

In 2026, weight-loss drugs will transition from a ‘luxury for the few’ to a ‘necessity for the many’.
We are entering an era where obesity, a long-standing human challenge, becomes medically controllable for the first time in history.

Data Source: The Economist “The World Ahead 2026” (Science & Technology Section)